SCHEMBL526587

SCHEMBL526587

O=Cc1ccncc1Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30570000 1.00
SCHEMBL30431215 0.84
SCHEMBL567215 0.84
Hydrochloric Acid SCHEMBL17558821 0.82 TRIM24 (0.41)
Bromide SCHEMBL18228259 0.82 TRIM24 (0.41)
SCHEMBL2600757 0.80 KMT2A (0.46)
SCHEMBL29955436 0.80 KMT2A (0.46)
SCHEMBL25402891 0.79
SCHEMBL768221 0.79
SCHEMBL1368649 0.76 CCNC (0.56)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 595 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108350034-B Antimicrobial polymyxin derived compounds 莫纳什大学 2022-03-11 CN claimed
CN-113493407-A Pyridine compound and preparation method and pharmaceutical application thereof 中国医学科学院药物研究所 2021-10-12 CN claimed
CN-108440397-B 3- (naphthalene-1-methyl substituted) pyridine derivative and synthesis method and application thereof 南方医科大学 2020-06-05 CN claimed
WO-2019169890-A1 3-(NAPHTHALENE-1-METHYL SUBSTITUTED)PYRIDINE DERIVATIVE, SYNTHETIC METHOD THEREFOR AND USE THEREOF 南方医科大学 2019-09-12 WO claimed
EP-4161642-B1 N-PHENYLAMINOCARBONYL PYRIDINO- , PYRIMIDINO AND BENZO-TROPANES AS MODULATORS OF GPR65 PATHIOS THERAPEUTICS LTD (GB) 2026-05-27 EP disclosed
EP-4126835-B1 INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR JANSSEN PHARMACEUTICA NV (BE) 2026-02-18 EP disclosed
US-12516038-B2 Inhibitors of antigen presentation by HLA-DR JANSSEN PHARMACEUTICA NV (BE) 2026-01-06 US disclosed
US-12441726-B2 Compounds and uses thereof FOGHORN THERAPEUTICS, INC. (US) 2025-10-14 US disclosed
US-20250289789-A1 REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. 2025-09-18 US disclosed
EP-4587014-A2 C5AR1 ANTAGONISTS AND USES THEREOF Vanqua Bio, Inc. (US) 2025-07-23 EP disclosed
US-20250215029-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. 2025-07-03 US disclosed
EP-4573096-A1 INHIBITORS OF MYELOPEROXIDASE Astrazeneca AB (SE) 2025-06-25 EP disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed
US-6057345-A ANTAGONISTS OF THE PAIN ENHANCING EFFECTS OF E-TYPE PROSTAGLANDINS; USED IN PAIN RELIEF ZENECA LIMITED (GB) 2000-05-02 US disclosed
US-5834468-A ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, ANALGESICS TREATING RHEUMATIC DISEASE, BONE DISORDER, INJURIES ZENECA LIMITED (GB) 1998-11-10 US disclosed
EP-0752421-A1 Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists ZENECA LIMITED (GB) 1997-01-08 EP disclosed
US-4761480-A DOPAMINE-BETA-HYDROXYLASE INHIBITORS SMITHKLINE BECKMAN CORPORATION (US) 1988-08-02 US disclosed
US-4732901-A BRONCHODILATORS BEECHAM GROUP P.L.C. (GB) 1988-03-22 US disclosed
EP-0214740-A2 Dopamine-beta-hydroxylase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 1987-03-18 EP disclosed
US-4634711-A ENZYME INHIBITORS SMITHKLINE BECKMAN CORPORATION (US) 1987-01-06 US disclosed